CSL Ltd. (CSL.AX, CSLLY.PK), an Australian biotechnology company, in collaboration with Arcturus Therapeutics (ARCT), a leader in self-amplifying mRNA (sa-mRNA) technology, announced on Friday that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted approval and authorization for their updated sa-mRNA COVID-19 vaccine, KOSTAIVE.KOSTAIVE, the pioneering sa-mRNA COVID-19 vaccine globally, was first approved for adults aged 18 and older in Japan in November 2023. This updated version of the vaccine is specifically designed to provide protection against the JN.1 lineage of Omicron subvariants for the same age group.In partnership with CSL, Meiji Seika Pharma will commence distribution of the updated vaccine ahead of Japan’s October COVID-19 vaccination campaign. This rollout marks the world’s first availability of a commercial sa-mRNA COVID-19 vaccine for adults aged 18 and over.The approval follows robust clinical evidence confirming the vaccine’s safety and effectiveness. Published data indicate that the sa-mRNA COVID-19 vaccine demonstrates superior immunogenicity against the Omicron BA 4/5 variants when compared to a conventional mRNA booster. Additionally, follow-up data reveal that the vaccine offers immunity lasting up to one year.The material has been provided by InstaForex Company – www.instaforex.com
- Czech Retail Sales Growth Accelerates in August, Reaching 5.30% - October 8, 2024
- Czech Unemployment Rate Sees Slight Uptick in September - October 8, 2024
- France Sees Rise in Imports: August Figures Show a Notable Increase - October 8, 2024
